Trial Profile
An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Jan 2016
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary) ; Mesenchymal stem cell therapy (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 22 Jan 2016 New trial record